Shares of Becton Dickinson and Co (NYSE:BDX) have been given a consensus rating of “Hold” by the eighteen ratings firms that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, seven have issued a hold rating and nine have issued a buy rating on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $273.79.
BDX has been the topic of a number of recent research reports. Zacks Investment Research lowered Becton Dickinson and from a “hold” rating to a “sell” rating and set a $245.00 price target on the stock. in a research note on Wednesday, May 27th. KeyCorp reiterated a “hold” rating on shares of Becton Dickinson and in a research report on Tuesday, May 12th. Raymond James decreased their price target on shares of Becton Dickinson and from $290.00 to $265.00 and set an “outperform” rating for the company in a research report on Thursday, June 25th. UBS Group raised their price target on shares of Becton Dickinson and from $260.00 to $265.00 and gave the company a “neutral” rating in a research note on Friday, May 8th. Finally, SVB Leerink boosted their price objective on shares of Becton Dickinson and from $262.00 to $277.00 and gave the stock a “market perform” rating in a research note on Wednesday, July 15th.
In other news, EVP Patrick Kaltenbach sold 1,272 shares of the firm’s stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $260.00, for a total value of $330,720.00. Following the completion of the sale, the executive vice president now directly owns 10,340 shares in the company, valued at approximately $2,688,400. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 0.12% of the stock is owned by corporate insiders.
Shares of Becton Dickinson and stock opened at $281.34 on Tuesday. The company’s 50 day moving average price is $250.93 and its two-hundred day moving average price is $250.95. The firm has a market capitalization of $76.29 billion, a P/E ratio of 84.74, a P/E/G ratio of 3.74 and a beta of 0.93. Becton Dickinson and has a fifty-two week low of $197.75 and a fifty-two week high of $286.72. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.98 and a quick ratio of 0.66.
Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.55 EPS for the quarter, beating the Zacks’ consensus estimate of $2.32 by $0.23. The company had revenue of $4.25 billion during the quarter, compared to analysts’ expectations of $4.10 billion. Becton Dickinson and had a return on equity of 15.75% and a net margin of 6.10%. Becton Dickinson and’s revenue was up 1.4% compared to the same quarter last year. During the same period in the prior year, the company earned $2.59 EPS. On average, analysts expect that Becton Dickinson and will post 10.35 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be issued a dividend of $0.79 per share. The ex-dividend date is Tuesday, September 8th. This represents a $3.16 annualized dividend and a dividend yield of 1.12%. Becton Dickinson and’s dividend payout ratio is currently 27.05%.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Read More: QQQ ETF
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.